Form 4: Director James Momtazee Adjusts Roivant Holdings

Director James C. Momtazee acquired 469 common shares of Roivant Sciences Ltd. as part of director compensation, with a portion withheld for taxes.

Summary

• Director James C. Momtazee received 469 common shares as part of the company's Non-Employee Director Compensation Plan.
• The shares were fully vested upon the grant date of April 17, 2026.
• A total of 94 shares were withheld by the company to satisfy tax obligations related to the vesting, resulting in a net increase of 375 shares.
• Following these transactions, the director's total beneficial ownership stands at 109,405 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation with no impact on company fundamentals.

Positives

• Director maintains a significant equity stake of 109,405 shares, aligning interests with shareholders.

Negatives

• None identified; this is a routine compensation-related transaction.

Risks

• None identified; this is a standard regulatory disclosure of director equity compensation.

Future Outlook

Not applicable; this is a retrospective disclosure of an equity transaction.

Industry Context

StockSavvy.ai notes that routine equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with long-term corporate performance.

Comparison to Industry Standards

• The use of net settlement for tax obligations is a standard administrative practice for equity-based compensation in publicly traded companies.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as the transaction represents standard director compensation.

Next Steps

• None; this is a completed transaction.

Key Dates

Keywords

Roivant Sciences, ROIV, Form 4, Insider Trading, Director Compensation, Equity Ownership